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STUDY PROTOCOL Open Access
Prognostic value of myocardial fibrosis in
severe aortic stenosis: study protocol for a
prospective observational multi-center
study (FIB-AS)
Giedrė Balčiūnaitė1* , Darius Palionis2, Edvardas Žurauskas3, Viktor Skorniakov4, Vilius Janušauskas1,
Aleksejus Zorinas1, Tomas Zaremba1,5, Nomeda Valevičienė2, Audrius Aidietis1, Pranas Šerpytis1, Kęstutis Ručinskas1,
Peter Sogaard1,5 and Sigita Glaveckaitė1
Abstract
Background: Adverse cardiac remodeling with a myocardial fibrosis as a key pathophysiologic component may be
associated to worse survival in aortic stenosis (AS) patients. Therefore, with the application of advanced cardiac
imaging we aim to investigate left ventricular myocardial fibrosis in severe AS patients undergoing aortic valve
replacement (AVR) and determine its impact with post-intervention clinical outcomes.
Methods: In a prospective, observational, cohort study patients with severe AS scheduled either for surgical or
transcatheter AVR will be recruited from two tertiary heart centers in Denmark and Lithuania. All patients will
receive standard of care in accordance with the current guidelines and will undergo additional imaging testing
before and after AVR: echocardiography with deformation analysis and cardiovascular magnetic resonance (CMR)
with T1 parametric mapping. Those undergoing surgical AVR will also have a myocardial biopsy sampled at the
time of a surgery for histological validation. Patients will be recruited over a 2-year period and followed up to 2
years to ascertain clinical outcomes. Follow-up CMR will be performed 12 months following AVR, and
echocardiography with deformation analysis will be performed 3, 12, and 24 months following AVR. The study
primary outcome is a composite of all-cause mortality and major adverse cardiovascular events.
Discussion: Despite continuous effort of research community there is still a lack of early predictors of left
ventricular decompensation in AS, which could improve patient risk stratification and guide the optimal timing for
aortic valve intervention, before irreversible left ventricular damage occurs. Advanced cardiac imaging and CMR
derived markers of diffuse myocardial fibrosis could be utilized for this purpose. FIB-AS study is intended to
invasively and non-invasively assess diffuse myocardial fibrosis in AS patients and investigate its prognostic
significance in post-interventional outcomes. The results of the study will expand the current knowledge of cardiac
remodeling in AS and will bring additional data on myocardial fibrosis and its clinical implications following AVR.
(Continued on next page)
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Background
Since increased afterload is the main pathophysiology of
aortic stenosis (AS) leading to the progressive develop-
ment of left ventricular (LV) structural and functional al-
terations, AS is regarded a disease of the aortic valve, as
well as of the myocardium [1]. The increasing wall stress
triggers cardiac fibroblasts to upregulate fibronectin syn-
thesis, with subsequent alteration in collagen architec-
ture and myocardial fibrosis, compromising systolic and
diastolic LV function [2]. Two distinct types of myocar-
dial fibrosis have been described: (i) diffuse myocardial
fibrosis and (ii) focal replacement fibrosis [3]. Focal re-
placement fibrosis can be detected by cardiovascular
magnetic resonance (CMR) with late gadolinium en-
hancement (LGE) and is observed in up to half of aortic
stenosis patients with non-infarct type being the most
prevalent [4]. Multicenter trials and meta-analyses have
shown that the presence and extent of LGE are associ-
ated with higher long-term all-cause and cardiovascular
mortality after aortic valve replacement (AVR), indicat-
ing more advanced myocardial injury [4, 5]. Focal myo-
cardial fibrosis has been demonstrated to be irreversible
following AVR [6, 7], resulting in incomplete LV recov-
ery and worse clinical outcomes, suggesting suboptimal
timing of aortic valve intervention in some patients. On
the contrary, diffuse interstitial fibrosis has been re-
ported to be reversible with afterload relief and could be
utilized as a potential marker of early LV dysfunction [8,
9]. However, the most recent study showed that regres-
sion of diffuse fibrosis may be incomplete in certain pa-
tients, leading to persistent LV systolic dysfunction and
worse survival [10]. Application of T1 mapping tech-
niques, which measures native and postcontrast T1 re-
laxation time or extracellular volume fraction (ECV),
facilitates non-invasive detection and quantification of
interstitial fibrosis with high spatial resolution [11–14].
Several studies in AS patients have reported that native
T1 and ECV values correlate with the degree of diffuse
myocardial fibrosis and predict cardiovascular events
and mortality [9, 10, 15]. Thus, myocardial fibrosis de-
tection by CMR is potentially useful for improving pa-
tient risk stratification and perhaps can justify earlier
aortic valve intervention, before extensive fibrosis and ir-
reversible myocardial damage develop.
Furthermore, because the subendocardial layer is the
first to be affected in AS, the longitudinal alignment of
myocardial fibers in this layer causes decreased longitu-
dinal contraction, an early sign of LV dysfunction. There
are data showing, that global longitudinal strain (GLS)
correlate with LV myocardial fibrosis and is a predictor
of adverse events in patients with severe AS [16, 17].
Novel diagnostic strategies and more accurate evaluation
of the disease severity and consequences of AS are needed
in the assessment of subclinical myocardial dysfunction and
the detection of myocardial fibrosis to challenge current
recommendations for the timing of AVR. To date there are
limited data on simultaneous assessment of diffuse myocar-
dial fibrosis by noninvasive multimodality imaging and
histological confirmation in severe AS. Optimal T1 map-
ping application also remains unclear, and data assessing its
prognostic value in severe AS are still lacking. Our multi-
center prospective trial aims to: (i) non-invasively assess
myocardial fibrosis and validate it against histological data
in patients undergoing surgical AVR and (ii) assess the im-
pact of myocardial fibrosis on clinical outcomes following
AVR in both surgical and TAVR cohorts.
Hypothesis
Primary hypothesis: diffuse and focal myocardial fibrosis in
patients with severe AS is associated with worse immediate
(in-hospital) and long-term clinical outcomes, all-cause mor-
tality, and major adverse cardiovascular events (MACEs).
Secondary hypotheses:
 The presence and extent of myocardial fibrosis are
associated with markers of LV decompensation.
 The presence and extent of myocardial fibrosis have
a negative effect on LV reverse remodeling and
patient functional recovery following AVR.
Study objectives
Primary objective:
 To evaluate the prognostic significance of
myocardial fibrosis in patients with severe AS
undergoing AVR.
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Secondary objectives:
 To identify parameters of multimodality imaging
[two-dimensional (2D) echocardiography with an
extended myocardial deformation analysis, 1.5 T
contrast-enhanced CMR with T1 parametric map-
ping] predictive of LV decompensation.
 To quantify LV reverse remodeling 12 months
following AVR through CMR and echocardiographic
measurements.
Methods
Study design
FIB-AS is a prospective, observational, cohort study with
clinical endpoints, conducted in two participating sites
(in Lithuania and Denmark) from tertiary care hospitals.
A total of 110 patients with severe AS undergoing AVR
will be recruited from both institutions, and their data
will be collected in a dedicated online database, REDCap
(Research Electronic Data Capture) [18]. The choice of
aortic valve intervention, either surgical or transcatheter,
will be based on the heart team’s decision in accordance
to current guidelines [19]. Standard work-up examina-
tions for surgical AVR or TAVR will be conducted, con-
sisting of coronary angiography, echocardiography,
computed tomography, electrocardiography, and blood
tests. Once consent is confirmed, and prior to the AVR
procedure (window of 0–30 days), a contrast-enhanced
CMR scan with T1 mapping will be performed, in addition
to the standard-of-care. A follow-up CMR scan will be per-
formed 1 year following AVR. Those undergoing surgical
AVR will also have a myocardial biopsy sampled at the time
of a surgery, which will be sent for histological evaluation.
Outcome assessments will continue for a total of 2 years
post-intervention. The study flow diagram is presented in
Fig. 1. Both sites have received approval from local ethics
committees (Approval Numbers: for Vilnius University
Hospital (VUH): 158200–18/9–1014-558; for Aalborg Uni-
versity Hospital (AAUH): N-20180081. All patients will give
written informed consent.
Study population
We will recruit patients with severe AS requiring AVR
according to current treatment recommendations [19].
We will exclude patients with obstructive coronary ar-
tery disease requiring revascularization or other signifi-
cant valvular pathology. The inclusion and exclusion
criteria are set in Table 1. The recruitment period will
be 24 months, from May 2019 to May 2021. We expect
Fig. 1 Flow diagram of FIB-AS study. Abbreviations: 6MWT- 6-min walking test, AS- aortic stenosis, BNP- brain natriuretic peptide, CAD- coronary
artery disease, LGE-CMR- late gadolinium enhancement cardiovascular magnetic resonance, MLHFQ- Minnesota Living with Heart Failure
Questionnaire, SAVR- surgical aortic valve replacement, VHD- valvular heart disease, TAVR- transcatheter aortic valve replacement, Tn-I- troponin I
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to enroll a total of 110 patients: 60 patients undergoing
surgical AVR and 50 patients undergoing TAVR.
Aortic valve replacement
Surgical AVR will be performed by standard midline
sternotomy or J mini sternotomy with cardiopulmonary
bypass and mild hypothermia. The St. Jude Medical Tri-
fecta aortic bioprosthesis (St. Jude Medical, Inc., St. Paul,
MN, USA) or mechanical CarboMedics Standard Aortic
Valve (CarboMedics, Inc.; Austin, Tex) prostheses of
varying sizes will be used according to the surgical
team’s or patient’s preference. TAVR will be performed
under conscious sedation. A balloon-expandable Ed-
wards Sapien-3 Ultra Valve system, size 23, 26, or 29
mm (Edwards Lifesciences Inc., Irvine, CA, USA), will be
deployed. Preferably a transfemoral route of access will
be used, when vascular access will be judged suitable.
Data collection
The risk of interventional mortality will be assessed by cal-
culating European System for Cardiac Operative Risk
Evaluation II (EuroSCORE II) risk scores and Society of
Thoracic Surgeons (STS) risk scores using the online cal-
culators available at http://www.euroscore.org/calc.html
[20] and at http://riskcalc.sts.org/stswebriskcalc [21]. Al-
though not designed for TAVR, the STS score has been
validated and proved as a sensitive predictor of 30-day
mortality and may be used in both SAVR and TAVR
groups [22]. New York Heart Association (NYHA) func-
tional class and 6-min walking test (6MWT) will be ap-
plied to assess patients’ functional capacity and performed
using standard method [23]. The Minnesota Living with
Heart Failure Questionnaire (MLHFQ) [24] will be used
to assess health-related quality of life from the patient’s
perspective, as it has been specifically validated in patients
with aortic valve disease [25].
Blood testing
Blood samples will be collected and levels of cardiac bio-
markers (B-type natriuretic peptide and troponin I) will
be tested at baseline and at each follow-up visit. In
addition, blood samples will be taken on the day of
CMR scanning to determine hematocrit and creatinine
concentration.
Echocardiography
Comprehensive transthoracic 2D echocardiography will
be performed using a commercially available Vivid ultra-
sound (S70, E9 or E95) systems (GE Healthcare, Horten,
Norway) and stored on a dedicated workstation for sub-
sequent off-line analysis. AS severity, LV systolic and
diastolic functions will be evaluated in accordance with
the echocardiographic guidelines [26–28]. Simpson’s bi-
plane method will be used to calculate LV ejection frac-
tion. The aortic valve area at the pre-interventional
assessment and the effective prosthetic orifice area in
the post-interventional assessment will be calculated
using the continuity eq.
2D speckle tracking echocardiography (STE)
From the 2D grey-scale images of the apical two-, three-,
and four-chamber views, left ventricular global longitu-
dinal strain (GLS) will be measured and processed off-
line using commercially available software (EchoPac
112.0.1, GE Medical Systems; Horten, Norway) [29]. The
frame rate will be adjusted to 50 to 80 frames/s. The
end-systole will be defined by detecting the closure click
on the spectral tracing of the pulsed-wave Doppler of
aortic valve flow. During analysis, the endocardial border
will be traced manually at an end-systolic frame, and the
software will automatically trace a region of interest that
includes the entire myocardium. The change in length
versus the initial length of the speckle pattern over the
cardiac cycle will be used to calculate longitudinal strain,
with myocardial lengthening or stretching represented as
positive strain and myocardial shortening defined as
negative strain. GLS will be acquired by the average re-
gional strain curves (16-segment model for 2D STE). 2D
STE analysis will be performed only in patients from
VUH by an accredited investigator (G.B.). Segments with
Table 1 Inclusion and exclusion criteria
Inclusion Criteria:
• Severe AS (defined as AVA ≤1 cm2 or AVA index (iAVA) ≤0.6 cm2/m2
as determined by ultrasound examination)
• Males and females of any ethnic group ≥18 years of age
• Signed an informed patient consent form
Exclusion Criteria:
• Unable to provide informed consent
• Severe valvular heart disease other than AS
• Coronary artery disease requiring revascularization
• History of myocardial infarction
• Prior cardiac surgery
• Severe renal impairment - eGFR < 30ml/min/1.73m2
• Any absolute contraindication to CMR
• Permanent atrial fibrillation
• Patient with implanted cardiac devices (pacemaker, ICD)
• Inherited or acquired cardiomyopathy
• Other medical conditions that limit life expectancy or preclude AVR
• Pregnant or nursing women
• Mental condition rendering the patient unable to understand the
nature, scope, and possible consequences of the study or to follow the
protocol
Abbreviations: AS- aortic stenosis, AVA- aortic valve area, iAVA- aortic valve
area index, AVR- aortic valve replacement, CMR- cardiovascular magnetic
resonance, eGFR- estimated glomerular filtration rate, ICD- implantable
cardioverter defibrillator
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poor quality tracking or aberrant curves despite manual
adjustment will be removed from analysis.
CMR protocol
Basic description
For each patient, baseline and 1-year post-interventional
CMR scans will be performed using standard protocols on
a 1.5 T Siemens Aera scanner (at VUH) or a 1.5 T GE Dis-
covery MR 450 scanner (at AAUH) with surface coils and
prospective ECG triggering [3, 9]. Both sites will use corre-
sponding CMR protocols. LV end-systolic and end-
diastolic diameters, as well as maximal (end-diastolic) wall
thickness, will be traced and recorded from the short-axis
and long-axis views of the standard ECG-gated steady
state-free precession cine sequence (8-mm slice thickness).
LV volumes, mass, and ejection fraction will be measured
using commercially available software (suiteHEART®, Neo-
Soft, USA or cmr42, Circle Cardiovascular Imaging Inc.,
Canada) from a stack of sequential 8-mm short axis slices
(0–2-mm gap) from the atrio-ventricular ring to the apex.
Measurements will be indexed to body surface area in m2
(using the DuBois and DuBois formula).
LGE imaging
For detection of delayed hyperenhancement, images will
be acquired 10–15 min after intravenous administration
of Gadobutrol (0.2 mmol/kg) (Gadovist; Bayer AG,
Germany) or Gadoteridol (0.2 mmol/kg) (Prohance;
Bracco Imaging, Sweden) using a breath-hold segmented
inversion recovery fast gradient echo sequence in the
short-axis and long-axis planes of the LV, with an 8-mm
slice thickness and 20% distance factor. The image pa-
rameters (VUH) are: repetition time of 700 ms, echo
time 1.42 ms, flip angle 45°, matrix 256 × 184, and field
of view 360 mm. For AAUH, the typical imaging param-
eters are as follows: repetition time 5.79 ms, echo time
2.72 ms, flip angle 15°, matrix 256 × 256, and field of
view 380 mm. The optimal inversion time will be opti-
mized for each patient to null normal myocardial signal,
ranging from 220 to 320ms (usually around 240 ms).
The region of myocardial fibrosis will be defined as the
sum of pixels with signal intensity above 5 standard de-
viations of the normal remote myocardium in each
short-axis slice. The presence of myocardial fibrosis will
be qualitatively determined by two independent readers,
blinded to clinical data (2 radiologists with > 10 years of
experience at VUH- N.V. and D.P., and 2 cardiologists
with 8–10 years of experience at AAUH- P.S. and T.Z.).
T1 mapping
The present study describes image acquisition parame-
ters by focusing on T1 mapping images, which will be
acquired in four-chamber long-axis and short-axis (at
the basal and midventricular levels) images before and at
15min after contrast administration. All T1 mapping im-
ages have been acquired using modified Look-Locker
inversion-recovery (MOLLI) [30, 31] using the Motion Cor-
rection technique (on the Siemens scanner). The following
readout parameters will be used: slice thickness: 8mm; flip
angle: 35; field of view: 384 × 327; effective TI: 193ms; voxel
size: 1.5 × 1.5 × 8mm; TR/TE: 312.64/1.33ms; partial Fou-
rier: 7/8; and parallel imaging factor: 2 (VUH) and slice
thickness 8mm, flip angle 35, matrix size 256 × 256, inver-
sion time 130ms, and FOV 380mm (AAUH).
Measurement of the ECV and native T1 values
The T1 maps will be generated from the CMR worksta-
tion after in-line motion correction just after image acqui-
sition (Siemens scanner) or in post-processing software
(GE scanner). Two blinded reviewers will independently
review all T1 mapping sequences. Regions of interest will
be drawn manually in the blood and septum at the mid-
ventricular level on the short-axis image, excluding the
myocardium with LGE for T1 measurements [13, 32]. Re-
gions of interest in the septum are chosen for myocardial
T1, because this area corresponds to the site of myocardial
biopsy. The regions of interest will be drawn on the com-
pact myocardium, and the border of the myocardium will
not be included. To measure the T1 value of blood, circu-
lar regions of interest will be positioned in the LV cavity,
avoiding papillary muscle (Fig. 2).
The ECV of the myocardium will be calculated as fol-
lows: ECV% = (ΔR1m/ΔR1b) x (1 - hematocrit level) ×
100, where R1 is 1/T1, R1m is R1 in the myocardium,
R1b is R1 in the blood, and ΔR1 is the change in relaxiv-
ity. The change in relaxivity (ΔR1) was determined using
the following equation: ΔR1 = R1post - R1pre, where
R1post and R1pre are the R1 after and before gadolin-
ium chelate administration, respectively [33]. Blood sam-
ples will be taken on the day of CMR scanning to
determine hematocrit and creatinine concentration. In-
terobserver agreement between 2 different experienced
observers will be assessed on different days for 10 ran-
domly selected patients. Figure 3 summarizes the CMR
sequences used in this study.
Histological analysis
In patients undergoing surgical AVR biopsy specimens
will be obtained under direct vision by the surgical team
using a surgical scalpel from the basal anteroseptum just
after removal of the diseased aortic valve. All myocardium
tissue samples will be fixed in 10% neutral buffered forma-
lin and embedded in paraffin. Sections of 3-μm thickness
will be made on a Leica RM2145 microtome and stained
by hematoxylin and eosin, Masson‘s trichrome, and Congo
red methods. Digital images will be captured by using the
Aperio Scan-Scope XT Slide Scanner (Aperio Technolo-
gies, Vista, CA, USA) under 20× objective magnification
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(0.5-μm resolution). Histological slides (typically measur-
ing 20–30 sq./mm) will be processed for evaluation of
myocardial fibrosis. An experienced (> 25 years of experi-
ence) histologist (E.Ž.) blinded to the clinical and CMR
data will investigate all biopsy specimens. The fraction of
myocardial volume occupied by collagen tissue (collagen
volume fraction) will be determined by quantitative
morphometry with an automated image analysis system
(HALO™) in sections stained with Masson’s trichrome.
Quantification of the myocardial fibrosis area will be per-
formed using HALO™ Classifier Module and HALO™ Area
Quantification v1.0 algorithms (IndicaLabs, NM, USA)
within manually selected regions of interest enclosing the
tissue section and excluding endocardium from the ana-
lysis. All study assessments are summarized in Table 2.
Outcome measures
Primary outcome measure: a composite of all-cause
mortality and MACEs (time frame: from 30 days up to
24months following AVR).
Secondary outcomes measures:
 In-hospital and 30-day all-cause mortality (time
frame: 30 days)
 Length of hospital stay
 Time to the event (death or MACE) (time frame: 24
months)
 Cardiovascular mortality (from 30 days up to 24
months following AVR)
Primary outcome endpoints will be defined according
to current guidelines: Valve Academic Research
Consortium-2 (VARC-2) definitions [34] and guidelines
for reporting mortality and morbidity after cardiac valve
interventions [35]. Cardiovascular mortality defined as:
(1) death due to proximate cardiac cause (e.g., myocar-
dial infarction, cardiac tamponade, worsening heart fail-
ure, and low cardiac output syndrome); (2) death caused
by non-coronary vascular conditions (e.g., pulmonary
embolism, stroke, aortic rupture, or vascular dissection);
(3) all procedure-related deaths; (4) all valve-related
deaths; and (5) sudden or unwitnessed death [35]. All-
cause mortality defined as the sum of cardiovascular and
non-cardiovascular deaths, with the latter defined as any
Fig. 2 CMR T1 assessment. To measure the T1 value, regions of interest will be drawn manually in the blood and septum at the midventricular
level on the short-axis, avoiding papillary muscle
Fig. 3 CMR protocol for FIB-AS study
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death in which the primary cause is clearly related to
other than cardiovascular condition. 30-day mortality
defined as death occurring within 30 days or during
index procedure hospitalization, if the postoperative
length of stay is longer than 30 days.
Clinical follow-up
Patients will be routinely followed and managed accord-
ing to available guidelines. Clinical outcome data will be
collected from patient clinical visits at 3, 12, and 24
months following AVR. Serum biomarker analysis and
2D echocardiography with STE analysis will be per-
formed at each follow-up visit. A second CMR scan will
be performed 1 year after AVR. The 6MWT will be per-
formed, and the MLHF questionnaire will be adminis-
tered at the 12-month follow-up visit. FIB-AS study
follows the standard protocol items: recommendation
for interventional trials (SPIRIT) guidelines [36]. The
study timeline is presented in Fig. 4.
Statistical analysis
 Linear regression analysis to model the relationship
between the extent of myocardial fibrosis and
patient outcomes.
 Univariate and multivariate regression analysis of
CMR-derived predictors of adverse clinical events.
 Comparison of clinical, serum, and imaging (CMR
and echocardiography) biomarker data between
patients with different extents of fibrosis.
The statistical analysis will be performed under the super-
vision of V.S. at the Institute of Applied Mathematics,
Vilnius University Faculty of Mathematics and Informatics.
Descriptive statistics will be used to summarize the demo-
graphic, clinical, and imaging data characteristics of each
patient. Categorical variables will be presented as the fre-
quency and percentage, and continuous variables will be
expressed as the mean and standard deviation or median
and interquartile range. The 95% confidence interval will be
reported for primary outcomes. Patients will be grouped,
depending on the presence and extent of histologically
measured myocardial fibrosis, and their clinical and im-
aging data will be compared for significant differences. Bi-
variate correlation analysis of the native T1, ECV, and GLS
values with the degree of histologically measured myocar-
dial fibrosis will be performed. Pearson or Spearman correl-
ation coefficient will be used as the measure of correlation.
To identify independent predictors of the degree of myo-
cardial fibrosis, multivariate stepwise regression analysis will
be performed separately for native T1, ECV, and GLS
values, along with demographic and clinical data. The com-
posite event will be assessed from a simple Cox model for
survival analysis using ECV, native T1, and GLS, and their
c-indexes will be compared for how well each marker pre-
dicts the clinical outcome. In addition, the Kaplan–Meier
method will be used for the cumulative survival analysis
with log-rank test to assess statistical differences between
the curves of patients with different degree of myocardial
fibrosis. A two-tailed p-value of < 0.05 will be considered
statistically significant. The statistical analysis will be per-
formed using the R language and environment for statistical
computing (version 3.5.1) [37].
Sample size justification
A sample size calculation was performed for the primary
outcome: a composite of all-cause mortality and MACEs
following AVR. To estimate the sample size required for
the detection of a hazard ratio for ECV% of 1.32, R pack-
age powerSurvEpi was used [38]. Calculations were made
assuming that the Cox proportional hazards regression
model applies and taking into consideration a correlation
of ECV% with other possible confounding covariates. On
the basis of previous studies [15, 17] and assuming that
the power of the test should be at least 0.8, a sample size
of 100 patients is required. After an adjustment for 10%
patient loss or withdrawal, a total sample size of 110 pa-
tients was selected. The selected sample size is comparable
to other studies testing the association of myocardial fi-
brosis with adverse clinical outcomes.
Study timetable
The ethics application was approved in March 2018.
Study enrollment started in May 2019, and recruitment
is expected to be completed in May 2021, with a further
Table 2 Study assessments
Demographic data and comorbidities
STS risk score
EuroSCORE II
Serum biomarkers:
▸ Brain natriuretic peptide
▸ Troponin I
Cardiovascular imaging biomarkers:
▸ Transthoracic 2D echocardiogram with strain analysis (GLS)
▸ 1.5 T contrast-enhanced CMR with T1 mapping (Native T1, ECV)
Myocardial histological analysis:
▸Quantitative myocardial fibrosis assessment (CVF)
Functional status and quality of life assessment:
▸New York Heart Association functional class
▸Minnesota Living with Heart Failure Questionnaire
▸6-min walking test
Abbreviations: 2D- two-dimensional, ECV- extracellular volume, EuroSCORE-
European System for Cardiac Operative Risk Evaluation, CMR- cardiovascular
magnetic resonance, CVF- collagen volume fraction, GLS- global longitudinal
strain, STS- Society of Thoracic Surgeons
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24months for follow-up, post-processing, and close-out
of the study. The main study paper will be submitted
within 6 months of the study close-out.
Dissemination of results
The study results will be presented to the participating
physicians and the general medical community. Follow-
ing the complete data collection, the manuscript(s)
based on the trial results will be submitted to peer-
reviewed journals. Authorship criteria as defined by the
International Committee of Medical Journal Editors will
be followed.
Discussion
FIB-AS is a study intended to investigate the role of
multimodality imaging in the assessment of myocardial
fibrosis in severe aortic stenosis patients and its prog-
nostic significance in post-interventional outcomes. We
sought to assess diffuse myocardial fibrosis by measuring
the ECV and native T1 values obtained from CMR with
T1 mapping and GLS from STE and to validate these re-
sults against the degree of myocardial fibrosis found
from the histological examination. In addition, we will
explore LV reverse remodeling following aortic valve
intervention and its associations with patient clinical re-
covery. The results of the study will expand the current
knowledge of cardiac remodeling in AS and will bring
additional data on myocardial fibrosis and its clinical im-
plications following AVR.
Strengths
 The present prospective multicenter study is
designed to explore associations between left
ventricular myocardial fibrosis and clinical outcomes
in severe AS patients undergoing AVR. It has clearly
established aims, inclusion and exclusion criteria, as
well as defined methods and endpoints.
Fig. 4 Standard protocol items: recommendation for interventional trials (SPIRIT) figure of participant timeline. Abbreviations: 2D- two-
dimensional, 6MWT- 6-min walking test, CMR- cardiovascular magnetic resonance, MACEs- major adverse cardiovascular events, m- months,
MLHFQ- Minnesota Living with Heart Failure Questionnaire. *Endomyocardial biopsy will be performed only in patients undergoing surgical AVR
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 The non-invasive measurement of myocardial fibro-
sis by CMR with T1 mapping is validated against in-
vasive histological assessment.
 The trial is restricted to isolated AS, excluding
cardiac pathologies which could possibly contribute
to myocardial fibrosis burden, such as obstructive
coronary heart disease and other significant valvular
heart diseases.
 Inclusion of both surgical and TAVR cohorts will
allow the investigation of patients with different risk
profiles.
Limitations
 The selected sample size may be inadequate to allow
a subgroup analysis.
 Limitations of CMR to establish diffuse and focal
fibrosis: no reference regions of normal myocardium
due to diffuse fibrosis, arbitrary selection of
threshold of signal intensity, overlap of T1 values
between normal and diseased myocardium.
 The FIB-AS study excludes patients with comorbidi-
ties, such as obstructive coronary artery disease, a
history of myocardial infarction, renal failure, and
persistent atrial arrhythmias; therefore, our results
should not be overgeneralized to a broader AS pa-
tient population.
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